On July 20, Keymed Biosciences (02162.HK) rose 7.1% in regular trading, trading at HK$87.9/share, with turnover of HK$53.46 million.

On the news front, the innovative drug sector saw broad-based strength as multiple top-tier public fund managers triggered mandatory disclosure thresholds for Hong Kong-listed innovative drug stocks, signaling strong institutional conviction. The rally was further underpinned by the company's recent profit alert, which projected H1 net profit of no less than RMB 1.2 billion, a dramatic turnaround from a loss of approximately RMB 79 million in the prior-year period. Core product Kanyueda recorded H1 revenue exceeding RMB 390 million, representing year-over-year growth of over 132%, with the commercial team now covering more than 1,600 hospitals across 260 cities.

Additionally, Goldman Sachs increased its position by 287,500 shares on July 13 at an average price of HK$81.19, lifting its stake to 5.00%. The confluence of earnings momentum, institutional accumulation, and sector-level fund rotation collectively drove the intraday advance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)